| 000 | 01675 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518003905.0 | ||
| 264 | 0 | _c20190924 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/CIRCULATIONAHA.117.033326 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMartin, Anne-Céline | |
| 245 | 0 | 0 |
_aManagement of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence. _h[electronic resource] |
| 260 |
_bCirculation _c08 2018 |
||
| 300 |
_a627-633 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xblood |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 | _aBlood Coagulation Tests |
| 650 | 0 | 4 |
_aCatheter Ablation _xadverse effects |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 |
_aHeparin _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntraoperative Care _xadverse effects |
| 650 | 0 | 4 |
_aMonitoring, Intraoperative _xmethods |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aThromboembolism _xetiology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGodier, Anne | |
| 700 | 1 | _aNarayanan, Kumar | |
| 700 | 1 | _aSmadja, David M | |
| 700 | 1 | _aMarijon, Eloi | |
| 773 | 0 |
_tCirculation _gvol. 138 _gno. 6 _gp. 627-633 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/CIRCULATIONAHA.117.033326 _zAvailable from publisher's website |
| 999 |
_c28971993 _d28971993 |
||